Taysha Gene Therapies EPS TSHA

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Taysha Gene Therapies' earnings per share was −$0.42 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.13.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.13	n/a	−$0.42
Q1 FY26	Mar 31, 2026	−$0.12	n/a	−$0.38
Q4 FY25	Dec 31, 2025	−$0.08	n/a	−$0.34
Q3 FY25	Sep 30, 2025	−$0.09	n/a	−$0.33
Q2 FY25	Jun 30, 2025	−$0.09	n/a	−$0.34
Q1 FY25	Mar 31, 2025	−$0.08	n/a	−$0.34
Q4 FY24	Dec 31, 2024	−$0.07	−130%	−$0.36
Q3 FY24	Sep 30, 2024	−$0.10	n/a	−$0.06
Q2 FY24	Jun 30, 2024	−$0.09	n/a	−$0.89
Q1 FY24	Mar 31, 2024	−$0.10	n/a	−$1.18
Q4 FY23	Dec 31, 2023	$0.23	n/a	−$1.36
Q3 FY23	Sep 30, 2023	−$0.93	n/a	−$2.57

Companies in Biotechnology nearest Taysha Gene Therapies' size, closest first, today.

Company	EPS, 12 months	Growth
TSHATaysha Gene Therapies	−$0.42
MGTXMeiraGTx	$0.71
VCELVericel	$0.46	+283% a year
ADMAAdma Biologics	$0.70	−18% a year
PLXProtalix BioTherapeutics	$0.23	+283% a year
KRYSKrystal Biotech	$7.98	+62% a year
RGENRepligen	$0.73
TECHBIO-TECHNE	$1.15	+150% a year
Peer median	$0.71

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.